Survodutide Dosing Calculator

Dose

Dose escalation starting at 0.6 mg weekly SC, escalating through intermediate steps to target maintenance doses of 0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg weekly. The 4.8 mg dose produced the highest weight loss (approximately 14.9% at 46 weeks).

Frequency

Once weekly subcutaneous injection

Duration

46 weeks in the Phase 2 COURAGE trial; ongoing treatment in Phase 3 ACHIEVE program

The 0.6 mg dose served as both a starting and low-dose maintenance arm. Dose escalation was performed in a stepwise fashion to minimize GI adverse events. The COURAGE trial demonstrated dose-dependent weight loss across all survodutide arms. Phase 3 trials are evaluating doses up to 6.0 mg with optimized escalation schedules.

Dose

Dose escalation to target maintenance doses of 2.4 mg, 4.8 mg, or 6.0 mg weekly SC. The 6.0 mg dose was evaluated exclusively in the MASH trial and represents the highest dose studied to date.

Frequency

Once weekly subcutaneous injection

Duration

48 weeks in the Phase 2b MASH trial

The 4.8 mg dose demonstrated 47% MASH resolution rate and approximately 64% relative liver fat reduction. The 6.0 mg dose arm was included to explore higher exposure in the MASH population. All dose groups showed dose-dependent improvements in liver histology and biomarkers.

Dose

Dose escalation from 0.6 mg up to 6.0 mg weekly SC with optimized titration schedules designed for improved GI tolerability based on Phase 2 experience. Specific escalation steps and timing are under evaluation.

Frequency

Once weekly subcutaneous injection

Duration

Ongoing; expected treatment durations of 52-72 weeks or longer

The Phase 3 program uses more gradual dose escalation than Phase 2 to reduce GI adverse events and treatment discontinuation. Exact protocol details are subject to the clinical trial design and may vary across ACHIEVE sub-studies for obesity and MASH indications.

How much bacteriostatic water should I add to a 10 mg vial of Survodutide?

The community standard is 2 mL of bacteriostatic water for a 10 mg Survodutide vial. That gives a concentration of 5.00 mg/mL, so a 300 mcg dose is 6 units on a U-100 insulin syringe. Adding 1 mL instead doubles the concentration to 10.00 mg/mL and halves the draw to 3 units. Less water = smaller injection volume but harder to measure precisely.

How many syringe units is a 300 mcg dose of Survodutide?

On a standard U-100 insulin syringe, a 300 mcg dose of Survodutide is 6 units when the 10 mg vial is reconstituted with 2 mL of bacteriostatic water (5.00 mg/mL). If you use 1 mL of bac water instead, draw 3 units (10.00 mg/mL).

What is the standard Survodutide dose?

Community-reported protocols for Survodutide typically use 0.3 mg–6 mg once weekly via Subcutaneous. 300 mcg is a common starting dose. Based on Phase 2/3 trial doses with escalation from 0.3 mg; investigational compound only available through research chemical vendors or clinical trials

How long does a vial of Survodutide last at 300 mcg once weekly?

A 10 mg vial of Survodutide contains roughly 33 doses at 300 mcg per injection. At once weekly dosing, that is approximately 231 days (about 33 weeks) of supply per vial. Reconstituted Survodutide should generally be used within 28 days when refrigerated.

Where do you inject Survodutide?

Survodutide is typically injected subcutaneous. Common sites reported in the literature and by users include: Abdomen, Thigh, Upper arm. Rotate sites with each injection to reduce localized irritation.

Can I use sterile water instead of bacteriostatic water for Survodutide?

Bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) is strongly preferred for multi-dose vials like Survodutide because it inhibits microbial growth and lets a single vial be used over multiple weeks. Sterile water has no preservative and should generally be reserved for single-use preparations only.